Metformin-based nanomedicines for reprogramming tumor immune microenvironment
Theranostics,
Год журнала:
2024,
Номер
15(3), С. 993 - 1016
Опубликована: Дек. 2, 2024
Immunotherapy
has
transformed
current
cancer
management,
and
it
achieved
significant
progress
over
last
decades.
However,
an
immunosuppressive
tumor
microenvironment
(TME)
diminishes
the
effectiveness
of
immunotherapy
by
suppressing
activity
immune
cells
facilitating
immune-evasion.
Adenosine
monophosphate-activated
protein
kinase
(AMPK),
a
key
modulator
cellular
energy
metabolism
homeostasis,
gained
growing
attention
in
anti-tumor
immunity.
Metformin
is
usually
considered
as
cornerstone
diabetes
its
role
activating
AMPK
pathway
also
been
extensively
explored
therapy
although
findings
on
remain
inconsistent.
nanomedicine
formulation
found
to
hold
potential
reprogramming
TME
through
immunometabolic
modulation
both
cells.
This
review
elaborates
foundation
via
metformin-based
nanomedicines,
offering
valuable
insights
for
next
generation
therapy.
Язык: Английский
Dendrimer-Mediated Generation of a Metal-Phenolic Network for Antibody Delivery to Elicit Improved Tumor Chemo/Chemodynamic/Immune Therapy
ACS Applied Materials & Interfaces,
Год журнала:
2025,
Номер
unknown
Опубликована: Янв. 9, 2025
To
simplify
the
composition
and
improve
efficacy
of
metal-phenolic
network
(MPN)-based
nanomedicine,
herein,
we
designed
an
MPN
platform
to
deliver
programmed
death
ligand-1
(PD-L1)
antibody
(anti-PD-L1)
for
combined
tumor
chemo/chemodynamic/immune
therapy.
Here,
generation
5
poly(amidoamine)
dendrimers
conjugated
with
gossypol
(Gos)
through
boronic
ester
bonds
were
used
as
a
synthetic
polyphenol
coordinate
Mn2+,
then
complexed
anti-PD-L1
obtain
nanocomplexes
(for
short,
DPGMA).
The
prepared
DPGMA
exhibited
good
water
dispersibility
hydrodynamic
size
166.3
nm
tumor-microenvironment-responsive
drug
release
behavior.
integration
Gos
Mn2+
within
resulted
in
significant
inhibition
immunogenic
cell
activation
Gos-mediated
chemotherapy
Mn2+-catalyzed
chemodynamic
therapy,
respectively,
thereby
leading
dendritic
maturation
due
role
played
mediate
stimulator
interferon
genes
(STING)
pathway.
Moreover,
promoted
recognition
uptake
by
PD-L1-overexpressed
tumors
targeting,
achieving
combinational
therapy
mouse
melanoma
model,
where
immunotherapy
modes
three
parts
via
chemotherapy/CDT-mediated
ICD,
Mn2+-mediated
STING
activation,
antibody-mediated
immune
checkpoint
blockade.
With
Mn2+-endowed
r1
relaxivity
(1.38
mM–1
s–1),
can
also
be
MR
imaging.
dendrimer-mediated
may
developed
advanced
nanomedicine
tackle
other
cancer
types.
Язык: Английский
Multi‐Slit Diffraction in Scaled Space‐Time
Natural Sciences,
Год журнала:
2025,
Номер
unknown
Опубликована: Фев. 18, 2025
ABSTRACT
We
revisit
multi‐slit
diffraction
with
a
scaling
of
space
and
time
to
exploit
an
equivalence
wave
packets
describing
quantum
free
harmonic
oscillator
(HO)
motion.
introduce
co‐moving
frame
coordinates
define
effective,
time‐independent,
HO
potential
that
confines
directs
initially
displaced
along
the
classical
phase
oscillator.
‐slit
in
lab
from
slits
distant
detector
familiar
spreading
propagating
front
is
then
described
as
propagation
over
just
quarter
cycle
confined
well.
show
features
are
preserved
well
characterized
both
near
far
fields
by
trajectories
space.
Язык: Английский
PD-L1 blockade peptide-functionalized NaGdF4 nanodots for efficient magnetic resonance imaging-guided immunotherapy for breast cancer
RSC Advances,
Год журнала:
2025,
Номер
15(12), С. 9027 - 9033
Опубликована: Янв. 1, 2025
PD-L1
blockade
peptide-functionalized
NaGdF
4
nanodots
were
demonstrated
as
an
efficient
nanomedicine
for
the
MRI-guided
immunotherapy
of
TNBC.
Язык: Английский
Rational Construct of Extracellular Matrix Mimics via Peptide-Co-assembling Nanofibers for Efficient Bone Regeneration
Advanced Fiber Materials,
Год журнала:
2025,
Номер
unknown
Опубликована: Апрель 2, 2025
Язык: Английский
Hypoxia-responsive oncolytic conjugate triggers type-II immunogenic cell death for enhanced photodynamic immunotherapy
Journal of Controlled Release,
Год журнала:
2025,
Номер
unknown, С. 113717 - 113717
Опубликована: Апрель 1, 2025
Язык: Английский
Peptide-based drugs in immunotherapy: current advances and future prospects
Dipanjan Karati,
Shreyasi Meur,
Soumi Das
и другие.
Medical Oncology,
Год журнала:
2025,
Номер
42(5)
Опубликована: Апрель 23, 2025
Язык: Английский
Therapeutic peptides: chemical strategies fortify peptides for enhanced disease treatment efficacy
Amino Acids,
Год журнала:
2025,
Номер
57(1)
Опубликована: Май 8, 2025
Язык: Английский
PD-L1-targeted polymer-peptide-immune nanomedicine synergizes radiotherapy for durable tumor control
Jincheng Du,
Chuwen Luo,
Ya Liu
и другие.
Bioactive Materials,
Год журнала:
2025,
Номер
51, С. 531 - 542
Опубликована: Май 22, 2025
Язык: Английский
In situ tumor cell engineering reverses immune escape to enhance immunotherapy effect
Acta Pharmaceutica Sinica B,
Год журнала:
2024,
Номер
15(1), С. 627 - 641
Опубликована: Сен. 2, 2024
The
underlying
cause
of
low
response
rates
to
existing
immunotherapies
is
that
tumor
cells
dominate
immune
escape
through
surface
antigen
deficiency
and
inducing
immunosuppressive
microenvironment
(TIME).
Here,
we
proposed
an
in
situ
cell
engineering
strategy
disrupt
at
the
root
by
restoring
MHC-I/tumor-specific
complex
(MHC-I/TSA)
expression
promote
T-cell
recognition
silencing
CD55
increase
ICOSL+
B-cell
proportion
reverse
TIME.
A
doxorubicin
(DOX)
dual-gene
plasmid
(MAC
pDNA,
encoding
both
MHC-I/ASMTNMELM
CD55-shRNA)
coloaded
drug
delivery
system
(LCPN@ACD)
with
targeting
charge/size
dual-conversion
properties
was
prepared.
LCPN@ACD-induced
ICD
promoted
DC
maturation
enhanced
activation
infiltration.
LCPN@ACD
enabled
effective
MHC-I/TSA
on
cells,
increasing
ability
killing.
downregulated
expression,
increased
B
CTLs,
reversed
TIME,
thus
greatly
improving
efficacy
αPD-1
CAR-T
therapies.
application
this
eliminated
source
escape,
providing
new
ideas
for
solving
challenges
clinical
immunotherapy.
Язык: Английский